scholarly article | Q13442814 |
P50 | author | Dewi Vernerey | Q116878139 |
Adriana Zeevi | Q64123938 | ||
P2093 | author name string | Xavier Jouven | |
Christophe Legendre | |||
Alexandre Loupy | |||
Carmen Lefaucheur | |||
Jean-Paul Duong van Huyen | |||
Olivier Aubert | |||
Denis Glotz | |||
Denis Viglietti | |||
Carol Bentlejewski | |||
Clément Gosset | |||
P2860 | cites work | Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization | Q86568728 |
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation | Q86932430 | ||
C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study | Q86955576 | ||
Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients | Q87006000 | ||
Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients | Q87395286 | ||
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 | ||
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation | Q34382549 | ||
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. | Q35027253 | ||
Humoral theory of transplantation | Q35142603 | ||
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts | Q35790552 | ||
Anti-HLA antibody analysis and crossmatching in heart and lung transplantation | Q35808818 | ||
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers | Q35927436 | ||
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. | Q36514864 | ||
Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients | Q36772957 | ||
Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. | Q37155993 | ||
Update on Alloantibodies in Solid Organ Transplantation | Q38568370 | ||
Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. | Q40990548 | ||
The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation | Q41150961 | ||
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. | Q41228171 | ||
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification | Q43674377 | ||
Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients | Q43681319 | ||
Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies | Q43772409 | ||
Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation | Q44557532 | ||
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. | Q46060462 | ||
Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. | Q46174297 | ||
Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival | Q47331305 | ||
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients | Q48397261 | ||
The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody | Q68076654 | ||
The limitations of risk factors as prognostic tools | Q79445507 | ||
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA) | Q83101436 | ||
HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls | Q84291597 | ||
P433 | issue | 2 | |
P304 | page(s) | 702-715 | |
P577 | publication date | 2016-08-04 | |
P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
P1476 | title | Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss | |
P478 | volume | 28 |
Q64067275 | A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation |
Q33865743 | An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies |
Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
Q39445381 | Application, technical issues, and interpretation of C1q for graft outcome |
Q54589598 | Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs. |
Q90265882 | CXCR5+PD1+ICOS+ Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation |
Q37641415 | Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine |
Q90428801 | Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients |
Q55509898 | Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. |
Q54969814 | Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. |
Q58488462 | Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure |
Q38861456 | De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. |
Q101038727 | Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation |
Q47563660 | Desensitisation strategies in high-risk children before kidney transplantation. |
Q49719376 | Differential effects of donor-specific HLA antibodies in living- versus deceased-donor transplantation. |
Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
Q92803508 | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
Q39366464 | Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans |
Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
Q52373711 | HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. |
Q64113679 | HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway |
Q58559130 | Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies |
Q64899061 | Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation. |
Q92558904 | Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies |
Q47595221 | T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. |
Q30397251 | The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies |
Q101131721 | The challenge of using the virtual crossmatch as a singular tool for the detection of Anti-HLA antibodies- A study from a tertiary care institute from South India |
Q50504222 | Utility of protocol kidney biopsies for de novo donor-specific antibodies. |
Q89049434 | Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation |